收入
成本
利润
| Item | Category | Value | YoY |
|---|---|---|---|
| Total revenues | revenue | 12.22B | 2.77% |
| Earnings/(loss) before income taxes | profit | 3.11B | 85.80% |
| Total expenses | cost | 9.11B | -10.85% |
| Other nonoperating income (expense) | revenue | 108.00M | -53.85% |
| Noncontrolling interest | cost | 6.00M | 50.00% |
| Net earnings/(loss) | profit | 2.19B | 80.66% |
| Income tax provision | cost | 919.00M | 99.35% |
| Aggregate | cost | 9.22B | |
| Net earnings/(loss) attributable to bms | profit | 2.20B | 81.75% |
| Cost of products sold | cost | 3.44B | 16.17% |
| Research and development | cost | 2.53B | 6.49% |
| Selling, general and administrative | cost | 1.79B | -9.78% |
| Amortization of acquired intangible assets | cost | 831.00M | -65.46% |
| Acquired iprd | cost | 633.00M | 141.60% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 8.33B | 1.18% |
| Non-US | 3.60B | 6.29% |
| Other Region | 290.00M | 7.01% |
| Others | 1.00M |
| Segment | Value | YoY |
|---|---|---|
| Eliquis | 3.75B | 24.78% |
| Opdivo | 2.53B | |
| Orencia | 964.00M | |
| Yervoy | 739.00M | |
| Pomalyst/Imnovid | 675.00M | -24.83% |
| Reblozyl | 615.00M | |
| Revlimid | 575.00M | -59.28% |
| Other Growth Brands | 514.00M | |
| Breyanzi | 359.00M | |
| Opdualag | 299.00M | |
| Camzyos | 296.00M | |
| Other Legacy Brands | 177.00M | -21.33% |
| Zeposia | 161.00M | |
| Abecma | 137.00M | |
| Sprycel | 119.00M | -58.97% |
| Sotyktu | 80.00M | |
| Abraxane | 74.00M | -70.75% |
| Opdivo Ovantig | 67.00M | |
| Krazati | 53.00M | |
| Cobenfy | 43.00M |
| Item | Category | Value | YoY |
|---|---|---|---|
| Cash and cash equivalents | assets | 15.73B | |
| Receivables | assets | 11.42B | |
| Other current assets | assets | 4.95B | |
| Inventories | assets | 2.76B | |
| Marketable debt securities | assets | 776.00M | |
| Total current assets | assets | 35.63B | |
| Goodwill | assets | 21.75B | |
| Other intangible assets | assets | 20.46B | |
| Property, plant and equipment | assets | 7.35B | |
| Other non-current assets | assets | 6.33B | |
| Deferred income taxes | assets | 4.96B | |
| Marketable debt securities | assets | 406.00M | |
| Total assets | assets | 96.89B | |
| Total liabilities | liabilities | 78.29B | |
| Beginning balance | liabilities | 18.60B | |
| Long-term debt | liabilities | 44.47B | |
| Total current liabilities | liabilities | 28.14B | |
| Other non-current liabilities | liabilities | 5.46B | |
| Deferred income taxes | liabilities | 225.00M | |
| Noncontrolling interest | liabilities | 48.00M | |
| Total bms shareholders’ equity | equity | 18.55B | |
| Treasury stock, common, value | equity | 43.59B | |
| Accumulated other comprehensive loss | equity | 1.51B | |
| Other current liabilities | liabilities | 19.34B | |
| Debt, current | liabilities | 4.51B | |
| Accounts payable | liabilities | 4.29B | |
| Aggregate | equity | 63.65B | |
| Capital in excess of par value of stock | equity | 46.27B | |
| Retained earnings | equity | 17.09B | |
| Common stock | equity | 292.00M |
| Item | Value |
|---|---|
| Net earnings/(loss) | 5.97B |
| Depreciation and amortization, net | 3.03B |
| Acquired iprd | 2.33B |
| Rebates and discounts | 1.96B |
| Impairment charges | 514.00M |
| Stock-based compensation | 420.00M |
| Contingent consideration fair value adjustments | 336.00M |
| Income taxes payable | 320.00M |
| Accounts payable | 88.00M |
| Other noncash income (expense) | -76.00M |
| Equity method investment, realized gain (loss) on disposal | -90.00M |
| Increase (decrease) in inventories | -255.00M |
| Increase (decrease) in receivables | -314.00M |
| Deferred income taxes | -573.00M |
| Increase (decrease) in other operating assets and liabilities, net | -597.00M |
| Divestiture gains and royalties | -880.00M |
| Item | Value |
|---|---|
| Sale and maturities of marketable debt securities | 1.57B |
| Divestiture and other proceeds | 792.00M |
| Proceeds from sales of equity investments | 61.00M |
| Payments to acquire property, plant, and equipment | -941.00M |
| Payments to acquire marketable securities | -1.92B |
| Payments to acquire businesses, net of cash acquired | -2.24B |
| Item | Value |
|---|---|
| Other short-term financing obligations, net | 431.00M |
| Stock option proceeds and other, net | -95.00M |
| Repayments of long-term debt | -872.00M |
| Payments of dividends | -3.78B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 10.35B |
| Cash and cash equivalents, end of period | 15.73B |
快速穿透 10-K/10-Q 复杂数据。通过利润表及资产负债表桑基图,与现金流量表瀑布图,一站式洞悉企业财务流向。
在左侧搜索公司并选择一份报告。
申请股票支持